Sign Up
Stories
Innovative Cancer Therapies Unveiled
Share
Advancements in Cancer Treatment and Mar...
Advancements in Gene Editing and Cancer ...
Autolus Thrives with $350M Offering and ...
AB-2100 Phase 1/2 Trial Initiated
AI-Powered Antigen Research Partnership
Adagene Advances Clinical Collaboration
Overview
API
EpimAb Biotherapeutics and Crossbow Therapeutics showcase novel T-cell engagers targeting cancer at AACR 2024 Annual Meeting.
Ask a question
How do T-cell engagers like EMB-07 and CBX-250 differ from traditional cancer treatments?
How might the development of targeted cancer treatments impact the future of oncology research and patient care?
What challenges might arise in translating preclinical success to clinical efficacy in cancer therapies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage